There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …

Purpose In light of recently published clinical reports and trials, the TheraSphere Global
Dosimetry Steering Committee (DSC) reconvened to review new data and to update …

Hepatocellular carcinoma (HCC) is the third most common cause of cancer‐related death
and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona …

Purpose To report long-term outcomes of radiation segmentectomy (RS) for early
hepatocellular carcinoma (HCC). The authors hypothesized that outcomes are comparable …

Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for
hepatocellular carcinoma (HCC). In this study, we present overall survival (OS) outcomes in …

Background & Aims Conventional transarterial chemoembolization (cTACE) is used to treat
patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive …

Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular
carcinoma (HCC)< 3 cm; there is interest in expanding the role of ablation to 3‐5 cm. RFA is …

Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a
major cause of cancer-related mortality for which liver resection is an important curative …